Upcoming webinar: Risks, Benefits, and Natural Alternatives to GLP-1 Weight-Loss Drugs

The new class of weight-loss medications are hailed as game-changing wonder drugs, but just how safe and effective are they? Why do most people stop taking them within months of starting? Why does weight loss plateau, and what happens when you quit? How can you control the short-term side effects, such as gastrointestinal symptoms and muscle loss (“Ozempic face”), and what are the long-term risks of taking these drugs?

The adverse health effects of obesity itself are so dire that, like bariatric surgery, one could argue that these weight-loss drugs should be considered as a last resort, but there are diet and lifestyle changes that can naturally restore our GLP-1 satiety circuits. In this in-depth, three-hour live webinar event, Dr. Greger exposes what’s really happening in our bodies when we take drugs like Ozempic, explains why we should be concerned about supplements purported to act as “nature’s Ozempic,” and discusses the foods, beverages, spices, and lifestyle habits that can actually boost GLP-1 activity, cut cravings, and accelerate the loss of body fat.

Register here:

If you have already read Dr. Greger’s OZEMPIC: Risks, Benefits, and Natural Alternatives to GLP-1 Weight-Loss Drugs ( ), please come with questions.

All CME attendees will receive Dr. Greger’s OZEMPIC: Risks, Benefits, and Natural Alternatives to GLP-1 Weight-Loss Drugs ( ) ebook as part of your registration.

Everyone who registers for the webinar will receive the recording a few days after it takes place.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Rochester Academy of Medicine and NutritionFacts.org. The Rochester Academy of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

• Subscribe:
• Donate:
• Podcast :
• Books:
• Shop:
• Facebook:
• Twitter:
• Instagram: